CIK 0001652130
- Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 364785571
- Phone
- +1 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 4 Open-market sale EVP, Chief Scientific Officer sold 8,966 shares at $12.18 ($109,206)
- 4 Open-market sale EVP, Chief Technical Officer sold 7,978 shares at an average $12.17 ($97,089)
- 4 Exercise or conversion EVP, Chief Medical Officer acquired 3,189 shares (option exercise)
- 4 Exercise or conversion President and CEO acquired 7,850 shares (option exercise)
- 4 Exercise or conversion EVP, Chief Scientific Officer acquired 3,500 shares (option exercise)
- 4 Open-market sale VP, Chief Accounting Officer sold 2,012 shares at $19.01 ($38,248)
- 4 Grant or award EVP, Chief Financial Officer acquired 66,324 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale EVP, Chief Technical Officer sold 405 shares at $22.93 ($9,287)
- 4 Grant or award VP, PAO and Interim PFO acquired 17,801 shares (grant or award)
- 4 Planned sale Director sold 1,505 shares at $25.00 ($37,625)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 15,409 shares (grant or award)
- 4 Grant or award Director acquired 7,737 shares (grant or award)
- 4 Grant or award Director acquired 7,737 shares (grant or award)
- 4 Grant or award Director acquired 7,737 shares (grant or award)
- 4 Grant or award Director acquired 7,737 shares (grant or award)
- 4 Grant or award Director acquired 7,737 shares (grant or award)
- 4 Grant or award Director acquired 7,737 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 4 of 18 · 353 filings